| Literature DB >> 34234877 |
Zheng Zhong1,2, Yukai Huang1, Yuqi Liu1, Junming Chen1,2, Meng Liu1, Qidang Huang1, Shaoling Zheng1, Xin Guo1, Weiming Deng1, Tianwang Li1,2.
Abstract
BACKGROUND: The C-reactive protein (CRP) to albumin (ALB) ratio (CAR) has emerged as a novel inflammatory biomarker. This study was designed to investigate the role of CAR in the disease activity of axial spondyloarthritis (axSpA).Entities:
Mesh:
Substances:
Year: 2021 PMID: 34234877 PMCID: PMC8216814 DOI: 10.1155/2021/6642486
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Demographic and laboratory data of the subjects.
| axSpA ( | Control ( | Reference interval |
| |
|---|---|---|---|---|
| Age (years) | 29.61 ± 7.92 | 31.15 ± 6.05 | 0.051 | |
| Sex (male/female) | 200/41 | 46/15 | 0.174 | |
| Neutrophils (×109/L) | 4.42 ± 1.36 | 3.72 ± 1.39 | 1.8-6.3 | <0.001 |
| Lymphocytes (×109/L) | 2.04 ± 0.63 | 2.15 ± 0.70 | 1.1-3.2 | 0.300 |
| Monocytes (×109/L) | 0.51 ± 0.18 | 0.38 ± 0.14 | 0.1-0.6 | <0.001 |
| Platelets (×109/L) | 278.28 ± 76.42 | 251.57 ± 45.24 | 125-350 | 0.032 |
| ALB (g/L) | 41.73 ± 5.45 | 46.11 ± 3.73 | 35-50 | <0.001 |
| CAR | 0.36 ± 0.51 | 0.06 ± 0.03 | <0.001 | |
| NLR | 2.39 ± 1.21 | 1.83 ± 0.73 | <0.001 | |
| PLR | 147.62 ± 61.39 | 128.88 ± 46.96 | 0.018 | |
| MLR | 0.26 ± 0.10 | 0.19 ± 0.06 | <0.001 | |
| ESR (mm/h) | 25.72 ± 25.08 | 8.06 ± 6.03 | 0-20 | <0.001 |
| CRP (mg/L) | 13.50 ± 17.92 | 2.66 ± 1.49 | 0-8 | <0.001 |
| Medications ( | ||||
| NSAIDs | 128 (53.11) | |||
| DMARDs | 96 (39.83) | |||
| Biologicals | 46 (19.09) |
ALB: albumin; CAR: C-reactive protein to albumin ratio; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; MLR: monocyte-lymphocyte ratio; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease modifying anti-rheumatic drugs.
Comparisons of the variables between axSpA of the active group and inactive group.
| Inactive group ( | Active group ( |
| |
|---|---|---|---|
| Age (years) | 29.22 ± 7.49 | 30.66 ± 8.95 | 0.255 |
| Sex (male/female) | 146/30 | 54/11 | 0.982 |
| Neutrophils (×109/L) | 4.37 ± 1.32 | 4.55 ± 1.47 | 0.415 |
| Lymphocytes (×109/L) | 1.98 ± 0.61 | 2.18 ± 0.66 | 0.022 |
| Monocytes (×109/L) | 0.50 ± 0.18 | 0.54 ± 0.20 | 0.192 |
| Platelets (×109/L) | 266.88 ± 68.77 | 309.15 ± 87.41 | <0.001 |
| ALB (g/L) | 42.83 ± 5.08 | 38.77 ± 5.37 | <0.001 |
| CAR | 0.26 ± 0.39 | 0.62 ± 0.69 | <0.001 |
| NLR | 2.40 ± 1.09 | 2.35 ± 1.51 | 0.230 |
| PLR | 145.09 ± 52.31 | 154.49 ± 81.15 | 0.504 |
| MLR | 0.26 ± 0.10 | 0.26 ± 0.10 | 0.452 |
| ESR (mm/h) | 21.51 ± 20.89 | 37.13 ± 31.39 | <0.001 |
| CRP (mg/L) | 10.36 ± 15.13 | 22.00 ± 21.86 | <0.001 |
| BASDAI | 1.28 ± 1.17 | 4.98 ± 0.84 | <0.001 |
| BASFI | 0.58 ± 0.98 | 2.31 ± 1.98 | <0.001 |
ALB: albumin; CAR: C-reactive protein to albumin ratio; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; MLR: monocyte-lymphocyte ratio; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index.
Figure 1Correlations of CAR, NLR, PLR, MLR with ESR, CRP, BASDAI, and BASFI in axSpA patients.
Figure 2ROC curve analysis of the variables for distinguishing axSpA disease activity.
Diagnostic values of variables for discriminating axSpA of the active group from the inactive group.
| AUC | 95% CI | Optimal cutoff point | Specificity | Sensitivity | |
|---|---|---|---|---|---|
| CAR | 0.701 | 0.638-0.758 | 0.3644 | 79.0% | 58.5% |
| NLR | 0.550 | 0.485-0.614 | 1.46 | 85.8% | 27.7% |
| PLR | 0.528 | 0.463-0.592 | 127.385 | 42.6% | 69.2% |
| MLR | 0.532 | 0.466-0.596 | 0.245 | 54.0% | 60.0% |
| ESR | 0.685 | 0.622-0.743 | 15.5 | 52.3% | 76.9% |
| CRP | 0.691 | 0.629-0.749 | 10.85 | 71.6% | 63.1% |
CAR: C-reactive protein to albumin ratio; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; MLR: monocyte-lymphocyte ratio; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; AUC: areas under the ROC curve; 95% CI: 95% confidence interval.
Binary logistic regression analysis of independent predictive factors for axSpA disease activity.
| Predictors | Univariate regression analyses | Multivariate regression analyses | ||||
|---|---|---|---|---|---|---|
|
| OR (95% CI) |
|
| OR (95% CI) |
| |
| Sex | 0.009 | 1.009 (0.473-2.153) | 0.982 | |||
| Age | 0.023 | 1.023 (0.987-1.060) | 0.211 | |||
| Neutrophils | 0.163 | 1.177 (0.432-3.204) | 0.750 | |||
| Lymphocytes | 0.699 | 2.012 (0.615-6.579) | 0.248 | |||
| Platelets | 0.706 | 2.026 (0.960-4.275) | 0.064 | |||
| CAR | 1.665 | 5.287 (2.866-9.753) | <0.001 | 1.542 | 4.673 (1.423-15.348) | 0.011 |
| NLR | 0.180 | 1.197 (0.568-2.522) | 0.637 | -0.316 | 0.729 (0.299-1.780) | 0.488 |
| PLR | 0.513 | 1.671 (0.912-3.061) | 0.097 | 0.013 | 1.013 (0.502-2.041) | 0.972 |
| MLR | 0.938 | 2.554 (1.081-6.035) | 0.033 | 0.613 | 1.845 (0.680-5.007) | 0.229 |
| ESR | 1.157 | 3.180 (1.750-5.777) | <0.001 | 0.516 | 1.675 (0.786-3.568) | 0.181 |
| CRP | 1.312 | 3.715 (2.044-6.754) | <0.001 | -0.225 | 0.798 (0.239-2.663) | 0.714 |
CAR: C-reactive protein to albumin ratio; NLR: neutrophil-lymphocyte ratio; PLR: platelet-lymphocyte ratio; MLR: monocyte-lymphocyte ratio; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; OR: odds ratio; 95% CI: 95% confidence interval.